Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...
GlobalData on MSN4d
GSK CEO addresses declining trust in vaccines following Trump re-electionGSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
That was the instant response of Emma Walmsley, CEO of GSK plc, reacting to breaking news from the U.S. that Donald Trump has won a second term in office.
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback